

Carla Abdelnour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6050173/publications.pdf>

Version: 2024-02-01

28
papers

886
citations

394421

19
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

1643
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	9.0	38
2	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 14.	6.2	10
3	Sex and gender considerations in clinical trials for Alzheimer's disease: Current state and recommendations. , 2021, , 309-327.		0
4	The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 95.	6.2	13
5	From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1541-1553.	2.6	11
6	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 109-110.	1.9	8
7	β -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.1	62
8	Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort. <i>Scientific Reports</i> , 2020, 10, 17721.	3.3	5
9	The combined effect of amyloid- β and tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 27, 102333.	2.7	22
10	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory [®]) for the early detection of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 25.	6.2	24
11	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. <i>Scientific Reports</i> , 2020, 10, 1580.	3.3	22
12	Association between retinal thickness and β -amyloid brain accumulation in individuals with subjective cognitive decline: Fundaci3 ACE Healthy Brain Initiative. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 37.	6.2	24
13	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. <i>Scientific Reports</i> , 2019, 9, 8698.	3.3	32
14	GBA and APOE ϵ 4 associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019, 9, 7013.	3.3	53
15	The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. <i>Scientific Reports</i> , 2018, 8, 3828.	3.3	28
16	The Role of Verb Fluency in the Detection of Early Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 611-619.	2.6	39
17	Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. <i>Alzheimer's and Dementia</i> , 2018, 14, 634-643.	0.8	33
18	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 340.	3.4	12

#	ARTICLE	IF	CITATIONS
19	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. <i>Scientific Reports</i> , 2018, 8, 16345.	3.3	52
20	Patient Engagement: The Fundaci3 ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1079-1090.	2.6	20
21	Safety, tolerability and immunogenicity of an active anti-A β 40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 12.	6.2	72
22	Impact of Recruitment Methods in Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 625-632.	2.6	26
23	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 787-795.	2.6	69
24	Challenges for Service Robots' Requirements of Elderly Adults with Cognitive Impairments. <i>Frontiers in Neurology</i> , 2017, 8, 228.	2.4	62
25	Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1099-1108.	2.6	9
26	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. <i>Movement Disorders</i> , 2016, 31, 1203-1208.	3.9	70
27	Concordance between Subjective and Objective Memory Impairment in Volunteer Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 1109-1117.	2.6	30
28	Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S99-S107.	2.6	40